A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya

Elizabeth A Juma, Charles O Obonyo, Willis S Akhwale, Bernhards R Ogutu, Elizabeth A Juma, Charles O Obonyo, Willis S Akhwale, Bernhards R Ogutu

Abstract

Background: Artemether/lumefantrine (AL) has been adopted as the treatment of choice for uncomplicated malaria in Kenya and other countries in the region. Six-dose artemether/lumefantrine tablets are highly effective and safe for the treatment of infants and children weighing between five and 25 kg with uncomplicated Plasmodium falciparum malaria. However, oral paediatric formulations are urgently needed, as the tablets are difficult to administer to young children, who cannot swallow whole tablets or tolerate the bitter taste of the crushed tablets.

Methods: A randomized, controlled, open-label trial was conducted comparing day 28 PCR corrected cure-rates in 245 children aged 6-59 months, treated over three days with either six-dose of artemether/lumefantrine tablets (Coartem) or three-dose of artemether/lumefantrine suspension (Co-artesiane) for uncomplicated falciparum malaria in western Kenya. The children were followed-up with clinical, parasitological and haematological evaluations over 28 days.

Results: Ninety three percent (124/133) and 90% (121/134) children in the AL tablets and AL suspension arms respectively completed followed up. A per protocol analysis revealed a PCR-corrected parasitological cure rate of 96.0% at Day 28 in the AL tablets group and 93.4% in the AL suspension group, p = 0.40. Both drugs effectively cleared gametocytes and were well tolerated, with no difference in the overall incidence of adverse events.

Conclusion: The once daily three-dose of artemether-lumefantrine suspension (Co-artesiane(R)) was not superior to six-dose artemether-lumefantrine tablets (Coartem) for the treatment of uncomplicated malaria in children below five years of age in western Kenya.

Trial registration: ClinicalTrials.gov NCT00529867.

Figures

Figure 1
Figure 1
The trial profile.
Figure 2
Figure 2
Proportion of children with fever during treatment.
Figure 3
Figure 3
Proportion of children with haemoglobin <10 g/dL.
Figure 4
Figure 4
Proportion of children with parasites during the first three days after treatment.

References

    1. Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC. The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg. 2003;68:386–390.
    1. Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2008;6:72. doi: 10.1186/1475-2875-6-72.
    1. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 2000;94:419–424. doi: 10.1016/S0035-9203(00)90126-3.
    1. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, Ibarra de Palacios P. Efficacy and safety of artemether-lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005;99:459–467. doi: 10.1016/j.trstmh.2004.09.013.
    1. Omari AA, Gamble C, Garner P. Artemether-lumefantrine for uncomplicated malaria: a systematic review. Trop Med Int Health. 2004;9:192–199. doi: 10.1046/j.1365-3156.2003.01186.x.
    1. Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005;95:194–203. doi: 10.1016/j.actatropica.2005.06.018.
    1. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJM. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474–1480. doi: 10.1016/S0140-6736(05)66417-3.
    1. van Vugt MV, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug resistant Plasmodium falciparum malaria. Am J Trop Med Hyg. 1999;60:936–942.
    1. Wasunna B, Zurovac D, Goodman CA, Snow RW. Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine. Malar J. 2008;7:29. doi: 10.1186/1475-2875-7-29.
    1. Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J. 2007;6:31. doi: 10.1186/1475-2875-6-31.
    1. Zurovac D, Njogu J, Akhwale W, Hamer DH, Snow RW. Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya. Trop Med Int Health. 2008;13:99–107.
    1. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004;71:525–530.
    1. Chinbuah AM, Gyapong JO, Pagnoni F, Wellington EK, Gyapong M. Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6–59 months old in Ghana. Trop Med Int Health. 2006;11:1003–1016. doi: 10.1111/j.1365-3156.2006.01654.x.
    1. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja M, Pagnoni F. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: A report from three study sites in sub-Saharan Africa. Malar J. 2008;7:190. doi: 10.1186/1475-2875-7-190.
    1. Chanda P, Hawela M, Kango M, Sipilanyambe N. Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Co-artesiane®) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia. Malar J. 2006;5:75. doi: 10.1186/1475-2875-5-75.
    1. Salah MT, Faroug M, Magzoub MM, Adam I. Efficacy of artemether-lumefantrine (Co-Artesiane®) suspension in the treatment of uncomplicated P. falciparum malaria among children under 5 years in eastern Sudan. Trop J Pharm Res. 2006;5:551–555.
    1. Kouame KJ, Houenou YA, Kouakou YG. Comparative study of artemether suspension monotherapy in 2 different regimes with a combination suspension containing artemether-lumefantrine for the treatment of simple childhood malaria in Abidjan, Ivory Coast. 2003. Report, Dafra Pharma.
    1. Ndenga B, Githeko A, Omukunda E, Munyekenye G, Atieli H, Wamai P, Mbogo C, Minakawa N, Zhou G, Yan G. Population dynamics of malaria vectors in western Kenya highlands. J Med Entomol. 2006;43:200–206. doi: 10.1603/0022-2585(2006)043[0200:PDOMVI];2.
    1. Ogutu BR, Nzila AM, Ochong E, Mithwani S, Wamola B, Olola CH, Lowe B, Kokwaro GO, Marsh K, Newton CR. The role of sequential administration of sulfadoxine-pyrimethamine following quinine in the treatment of severe falciparum malaria in children. Trop Med Int Health. 2005;10:484–488. doi: 10.1111/j.1365-3156.2005.01415.x.
    1. Obonyo CO, Ochieng F, Taylor WR, Ochola SA, Mugitu K, Olliaro P, ter Kuile F, Oloo AJ. Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003;97:585–591. doi: 10.1016/S0035-9203(03)80038-X.
    1. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002;359:1365–1372. doi: 10.1016/S0140-6736(02)08348-4.
    1. World Health Organization . Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Vol. 50. Geneva, World Health Organization; pp. 1–68. WHO/HTM/RBM/2003.
    1. World Health Organization . Report of a WHO Technical Consultation. Vol. 35. Geneva, World Health Organization; Antimalarial Drug Combination Therapy. WHO/CDS/RBM/2001.
    1. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, Viriyakosol S. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 1999;93:369–374. doi: 10.1016/S0035-9203(99)90120-7.
    1. Williams HN, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan. 2004;19:356–370. doi: 10.1093/heapol/czh051.
    1. Njau JD, Goodman CA, Kachur SP, Mulligan J, Munkondya JS, McHomvu N, Abdalla S, Bloland P, Mills A. The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in Tanzania. Malar J. 2008;7:74. doi: 10.1186/1475-2875-7-4.
    1. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother. 2007;8:75–94. doi: 10.1517/14656566.8.1.75.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する